### Check for updates

### **OPEN ACCESS**

EDITED BY Zhiyuan Wu, Harvard University, United States

REVIEWED BY Manoj Kumar Mahata, Belle Vue Clinic, India Xuan Deng, Capital Medical University, China

CORRESPONDENCE Hongying Jia i jiahongying@sdu.edu.cn Fengxue Shi fxshi1211@163.com Weiwei Chi 202259050001@sdu.edu.cn

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 21 October 2024 ACCEPTED 03 January 2025 PUBLISHED 27 January 2025

#### CITATION

Qiao J, Chen X, Pang J, Fei H, Liu Z, Cheng F, Chen Q, Zhao Y, Shi F, Jia H and Chi W (2025) Relationship between triglyceride glucose-body mass index baselines and variation with future cardiovascular diseases risk in the middle-aged and elderly individuals. *Front. Endocrinol.* 16:1514660. doi: 10.3389/fendo.2025.1514660

#### COPYRIGHT

© 2025 Qiao, Chen, Pang, Fei, Liu, Cheng, Chen, Zhao, Shi, Jia and Chi. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Relationship between triglyceride glucose-body mass index baselines and variation with future cardiovascular diseases risk in the middle-aged and elderly individuals

Junpeng Qiao<sup>1†</sup>, Xueyu Chen<sup>1†</sup>, Jinhong Pang<sup>1†</sup>, Haicheng Fei<sup>1</sup>, Zhang Liu<sup>1</sup>, Fang Cheng<sup>1</sup>, Qiaoqiao Chen<sup>1</sup>, Yingying Zhao<sup>1</sup>, Fengxue Shi<sup>2\*</sup>, Hongying Jia<sup>1,3\*</sup> and Weiwei Chi<sup>1,4\*</sup>

<sup>1</sup>Department of Epidemiology and Health Statistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China, <sup>2</sup>Department of Clinical Skills Center, School of Clinical Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China, <sup>3</sup>The School Hospital, Shandong University, Jinan, Shandong, China, <sup>4</sup>National Administration of Health Data, Jinan, Shandong, China

**Background:** Cardiovascular diseases (CVDs) are gradually becoming the leading cause of morbidity and mortality among chronic non-communicable diseases. Previous studies have found that the TyG index is an effective alternative indicator for insulin resistance (IR) and is associated with cardiovascular events. Additionally, obesity directly or indirectly increases the risk of developing CVDs. Up to now, studies on the combined effects of these factors are insufficient, and the conclusions are not yet consistent. This study aims to analyze whether the baseline levels and fluctuations of triglyceride glucosebody mass index (TyG-BMI) are associated with the incidence of CVDs and their subtypes in a prospective cohort of middle-aged and elderly individuals.

**Methods:** The data for this study were obtained from the China Health and Retirement Longitudinal Study (CHARLS), which is an ongoing nationally representative prospective cohort study. After excluding participants with partially missing variables that could affect the study results, this study ultimately included 7,072 participants, with data records spanning from 2011 to 2020. The exposures were TyG-BMI and the change in TyG-BMI from 2011 to 2015. The TyG-BMI index was calculated as TyG index multiply BMI. The change of TyG-BMI was categorized using K-means clustering and baseline TyG-BMI was grouped based on quartiles. We used Cox proportional hazards models to evaluate the relationship between baseline quartiles of the TyG-BMI index and its variability with CVDs and their subtypes.

**Results:** Among the 7,072 participants (mean age of 59.1  $\pm$  9.3 years), 3330 (47%) were male. During an average follow-up of 7.1 years, 1,774 (25.1%) participants developed new-onset cardiovascular diseases. After stratification by baseline TyG-BMI quartiles, higher TyG-BMI levels were associated with an increased risk of CVDs, The hazard ratio (HR) and 95% confidence interval (95% CI) for the highest quartile group were 1.69 (1.44-2.00). After adjusting for potential

confounding factors, compared to participants with consistently low TyG-BMI levels, those with moderate TyG-BMI levels and a slowly increasing trend had an HR of 1.27 (95% CI 1.10-1.47), while those with the highest TyG-BMI levels and a slowly decreasing trend had an HR of 1.52 (95% CI 1.26-1.83).

**Conclusion:** Material changes in the TyG-BMI are independently associated with the risk of CVDs in middle-aged and elderly individuals. Detecting long-term changes in the TyG-BMI may aid in the early identification of high-risk individuals and help prevent the occurrence of various cardiovascular diseases.

#### KEYWORDS

triglyceride glucose-body mass index, cardiovascular disease, K-means clustering, CHARLS, middle and elderly age

### Background

CVDs are gradually becoming the most common cause of morbidity and mortality among chronic non-communicable diseases in both China and globally (1–5). According to reports, in 2019, the number of deaths from cardiovascular diseases worldwide reached 19 million (6). Although some studies indicate that the occurrence of CVDs is associated with various risk factors such as age, obesity, hypertension, diabetes, severe stress experiences, and rheumatoid arthritis, etc (7–9), recent research has found that individuals without these risk factors may still be at risk for CVDs (10). Therefore, there is still a lack of scientifically reliable, direct, and simple indicators to effectively and sensitively alert individuals to the severe risk of CVDs (11).

Insulin resistance (IR) refers to a pathophysiological condition in which cells fail to respond normally to insulin. IR as a key factor in metabolic disorders, triggers the onset of CVDs (12, 13). It not only amplifies the correlation between traditional factors such as obesity, dyslipidemia, hypertension and CVDs, but also increases the risk of CVDs by influencing non-traditional factors, such as microalbuminuria (14, 15). The hyperinsulinemic-euglycemic clamp (HEC) is considered the gold standard for assessing IR (16); however, this method is complex and expensive, limiting its widespread clinical application. As an economically effective alternative for assessing IR, the triglyceride-glucose (TyG) index can be easily obtained from routine clinical laboratory tests, and research has demonstrated its association with the incidence and progression of CVDs (17, 18).

Recently, a study found that combining the TyG index with BMI as a reliable alternative indicator for the early detection of insulin resistance is effective. This measure is calculated by multiplying the TyG index by BMI, incorporating multiple clinical indicators such as BMI, blood glucose, and lipid levels, thereby enhances its predictive ability (19). Moreover, studies have shown that TyG-BMI has been significantly associated with diabetes, kidney disease, and hypertension (20, 21). Although early studies have provided valuable insights, there is still controversy regarding the association between TyG-BMI and CVDs. Therefore, this study aims to investigate the relationship between baseline TyG-BMI and its variability with the incidence of CVDs in middle-aged and elderly populations.

### Materials and methods

### Study design and population

The CHARLS project aims to collect a set of high-quality microdata representing households and individuals aged 45 and above in China, so as to analyze the aging of Chinese population and promote interdisciplinary research on aging. The CHARLS is an ongoing survey with assessments conducted every 2 to 3 years, and it has released five waves data of national to date. The survey includes: basic demographic information of the respondents and their family structure, health status of the respondents, medical service utilization and insurance, employment, income, consumption, assets, retirement and pension, and so on. Additionally, CHARLS includes physical measurements and blood sample collection of the respondents. The CHARLS data can be freely downloaded from the official website (https:// charls.pku.edu.cn/index.htm).

Abbreviations: CHARLS, China Health and Retirement Longitudinal Study; CVDs, Cardiovascular diseases; CHD, coronary heart disease; TyG index, triglyceride–glucose index; BMI, body mass index; TyG-BMI, triglyceride glucose-body mass index; IR, Insulin resistance; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; UA, uric acid; HR, Hazard Ratio; 95% CI, 95% Confidence Interval; RCS, Restricted cubic splines.

10.3389/fendo.2025.1514660

Our research is a prospective cohort study based on the CHARLS database. This study utilized data from five waves. At baseline (wave1), a total number of 17,708 respondents completed a face-to-face computer-assisted personal interview, and the exclusion criteria were as follows: without blood samples; missing value of fasting blood glucose (FPG), triglyceride, body mass index; diagnosed with cardiovascular disease; with cancer; and having fewer than one follow-up record. A number of 7,072 participants were remained at baseline after exclusion criteria, and 4,151 subjects were used for correlation analysis between the variability of TyG-BMI and CVDs incidence. The detailed flowchart is shown in Figure 1.

### Diagnosis of CVDs

The outcome was the incidence of CVDs, including stroke and chronic heart disease (CHD). The diagnostic criteria for these diseases were: self-reported physician-diagnosed condition and currently use of medication for treating the diseases.

### Assessment of TyG-BMI

The TyG-BMI index was calculated as follows: TyG index =  $\ln [TG (mg/dL) \times FBG (mg/dL)/2]$ ; BMI = weight (kg)/height (m<sup>2</sup>);

TyG-BMI index = TyG index  $\times$  BMI. The Baseline TyG-BMI index was calculated by TyG index and BMI in baseline (2011).

### Covariant definition

The data of this study were collected by investigators recruited and trained by the CHARLS research team. Demographic backgrounds, health status, anthropometric information, and blood data were identified and matched by a unique ID code.

The participants health record information included age, gender, education level, marital status and personal living habits. Education level was divided into "primary school and below", "middle school" and "high school and above". According to the questionnaire, marital status was divided into married and unmarried. Smoking and drinking habits were classified as "current smoking, former smoking, never smoking", "current drinking, former drinking and never drinking".

Participants meeting any one of the following criteria were considered to have diabetes: FBG≥7.0mmol/L(126mg/dL), self-reported doctor-diagnosed diabetes, or currently use of anti-diabetic medication.

Subjects who meet one of the following criteria were considered to have dyslipidemia: total cholesterol (TC)  $\geq$  6.2mmol/L, high-density lipoprotein cholesterol (HDL-C) < 1.0 mmol/L, low-density lipoprotein cholesterol (LDL-C)  $\geq$  4.1 mmol/L, or triglyceride (TG)



Flowchart of the study participants selection. FBG, fasting blood glucose; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CVDs, cardiovascular diseases.

 $\geq$  2.3 mmol/L. Additionally, self-reported doctor-diagnosed dyslipidemia or currently using lipid-lowering medication were also considered to have dyslipidemia.

Used an Omron HEM-7200 sphygmomanometer to measure the blood pressure in sitting position, and use standard measurement method to examine the blood pressure three times at an interval of 45 seconds, and take the average blood pressure value of the three measurement results as the final blood pressure. Hypertension was defined as systolic blood pressure (SBP) $\geq$ 140mmHg, diastolic blood pressure (DBP)  $\geq$  90mmHg. We also classify participants who were diagnosed as hypertension by doctors or currently used antihypertensive drugs as hypertension group.

### Statistical analysis

Data analysis used various statistical methods. Data was tested for normality using the Kolmogorov-Smirnov test method. Mean and standard deviations (mean ± SD) were used to describe continuous characteristics, and percentages and frequencies (N, %) were used to describe the categorical characteristics. Characteristics were nonormally distributed, used median and interquartile ranges (IQR) were used for description. Participants was divided into four groups based on the quartiles of the baseline TyG-BMI index, with the first quartile (Q1) being the lowest group and the fourth quartile (Q4) being the highest group. One-way ANOVA was used to test differences between groups for continuous variables. Kruskal-Wallis rank sum test was used to analyze differences between groups for continuous variables with non-normal distribution, and  $\chi^2$  test was used for the analysis of categorical variables. In this study, the p-value for statistical tests is defined as " $p \le 0.05$  was considered to indicate a statistically significant difference".

In this study, the follow-up time was calculated from the baseline to the last follow-up time, during which CVDs events or survival status were recorded. Univariate and multivariate analysis used Cox proportional hazard models to verify the relationship between the TyG-BMI index and CVDs, including their subtypes. The results were presented as hazard ratios (HR) and 95% confidence intervals (95%CI), and forest plots were used to visualize the results. Then, subgroup analyses were conducted by gender (male, female) and age (younger than 60 years, older than 60 years) using Cox proportional-hazards models to verify the relationship between the TyG-BMI index and CVDs within each subgroup, and the results were presented by HR and 95%CI.

We use a restricted cubic spline (with 4 knots) to explore the dose-response relationship between the TyG-BMI index and the incidence of CVDs. In this study, we introduced an unsupervised machine learning method, k-means clustering (22), to classify the TyG-BMI from 2011 to 2015. The rationale for using this method was its high computational efficiency, the ability to generate easily interpretable data points, and its strong visualization capabilities (23). The core idea of the K-means algorithm is to divide the dataset into K clusters, each represented by a centroid, in order to minimize the total squared distance between the data points within each cluster and the centroid, thereby partitioning the data into K clusters. To perform this operation, the following 4 steps are

involved: a. Choose a predetermined number of clusters, K; b. Randomly select K data points as the initial centroids; c. Recalculate the centroid of each cluster by computing the average position of all data points within the cluster; d. Assign each data point to its nearest centroid. Steps c and d are repeated until the centroids no longer change or the preset maximum number of iterations is reached. All statistical analyses and plotting were performed by the R software (version 4.4.1, http://www.R-project.org/).

### Result

# Baseline characteristics and CVDs incidence of participants according to baseline TyG-BMI quartiles

A total of 7,072 subjects were included in the study (average age of 59.1  $\pm$  9.3 years, 52.9% female), the demographic information and clinical characteristics of the study participants are presented in Table 1. At baseline, the average TyG index was  $8.6 \pm 0.6$ , triglyceride level was 103 mg/dL, FPG level was  $108.4 \pm 30.7$  mg/dL, and the mean BMI was  $23.4 \pm 3.8 \text{ kg/m}^2$ . Compared with other groups, the highest level group was more likely to be female, had a higher level of education, and lower proportions of current smoking and alcohol drinking. We observed that the levels of FBG, TG, TC and LDL-C were also higher in the fourth group, additionally, which had higher prevalence rates of hypertension, dyslipidemia, and diabetes. After a 9-year follow-up, there were 1,774 (25.1%) new cases of CVDs. The incidence rates of heart disease and stroke were 19.2% and 8.9%, respectively, with the highest incidence rates in the fourth group. Based on the quartiles of TyG-BMI index, the incidence of CHD and stroke indicated significant differences among the groups (P<0.001).

# Association of baseline TyG-BMI index with incident CVDs

In this study, during an average follow-up of 7.1 years, the incidence of CVDs was 25.1%, and the Q1 to Q4 groups were 19.1%, 23.2%, 25.6%, and 32.5%, respectively. CHD and stroke were 19.2% and 8.9%, and the incidence rates in Q1-Q4 were CHD (Q1,14.9%; Q2,17.6%; Q3,19.2%; Q4,24.9%) and stroke (Q1,5.7%; Q2,8.0%; Q3,10.2%; Q4,11.6%), respectively.

Figure 2 shows the results of the Cox proportional hazards model. The results of the univariate Cox proportional hazards model analysis showed that compared to the lowest group (Q1), the highest TyG-BMI index levels group (Q4) was positively correlated with the risk of CVDs (HR 1.76; 95% CI 1.54–2.00). After covariates adjustment in model3, significant differences were observed in TyG-BMI index between Q2, Q3 and Q4 groups, compared with Q1 group. As the TyG-BMI index levels increased, compared with the lowest group, the adjusted hazard ratios (aHR) with 95% CI were 1.23(1.06-1.41), 1.33 (1.15-1.54), and 1.69(1.44-2.00), respectively. Similarly, for the incidence of CHD and stroke events, the quartiles of the TyG-BMI index were consistent with the overall CVDs results; indicating that higher TyG-BMI index levels were associated with higher risks of

TABLE 1 Baseline characteristics of study population and incidence of CVDs in TyG-BMI quartiles.

Characteristic	Overall	Q1(102.4-174.9)	Q2(174.9-197.9)	Q3(197.9-225.6)	Q4(225.6-608.1)	p-value <sup>c</sup>
n	7072	1768	1768	1768	1768	
Age(years) <sup>a</sup>	59.1 ± 9.3	61.5 ± 9.9	59.2 ± 9.3	58.4 ± 8.9	57.2 ± 8.4	< 0.001
Gender,n(%)						< 0.001
Male	3,330 (47.1%)	1,022 (57.8%)	873 (49.4%)	774 (43.8%)	661 (37.4%)	
Female	3,742 (52.9%)	746 (42.2%)	895 (50.6%)	994 (56.2%)	1,107 (62.6%)	
Marital status,n(%)						< 0.001
Married	6,271 (88.7%)	1,508 (85.3%)	1,555 (87.9%)	1,576 (89.1%)	1,632 (92.3%)	
Unmarried	801 (11.3%)	260 (14.7%)	213 (12.1%)	192 (10.9%)	136 (7.7%)	
Education levels,n(%)						< 0.001
Primary school or below	4,952 (70.0%)	1,348 (76.2%)	1,270 (71.8%)	1,195 (67.6%)	1,139 (64.4%)	
Middle school	1,414 (20.0%)	292 (16.6%)	343 (19.4%)	362 (20.5%)	417 (23.5%)	
High school or above	706 (10.0%)	128 (7.2%)	155 (8.8%)	211 (11.9%)	212 (12.1%)	
Smoking status,n(%)						< 0.001
Never smoker	4,321 (61.1%)	875 (49.5%)	1,044 (59.1%)	1,145 (64.8%)	1,257 (71.1%)	
Former smoker	578 (8.2%)	143 (8.1%)	122 (6.9%)	158 (8.9%)	155 (8.8%)	
Current smoker	2,173 (30.7%)	750 (42.4%)	602 (34.0%)	465 (26.3%)	356 (20.1%)	
Drinking status,n(%)						< 0.001
Never drinking	4,111 (58.1%)	951 (53.8%)	991 (56.1%)	1,036 (58.6%)	1,133 (64.1%)	
Former drinker	546 (7.7%)	147 (8.3%)	130 (7.4%)	127 (7.2%)	142 (8.0%)	
Current drinker	2,415 (33.9%)	670 (37.9%)	647 (36.5%)	605 (34.2%)	493 (27.9%)	
FPG (mg/dl) <sup>a</sup>	108.4 ± 30.7	99.6 ± 18.0	104.0 ± 23.6	108.6 ± 27.9	121.5 ± 42.9	< 0.001
TC (mg/dl) <sup>a</sup>	194.1 ± 37.8	184.7 ± 35.1	191.6 ± 37.5	196.9 ± 37.5	202.9 ± 38.7	< 0.001
TG (mg/dl) <sup>b</sup>	103 (73, 149)	73 (57, 93)	89 (69, 123)	112 (85, 156)	159 (117, 227)	< 0.001
HDL-C(mg/dl) <sup>a</sup>	51.8 ± 15.0	$60.0 \pm 15.4$	54.8 ± 14.1	49.3 ± 13.2	42 .9 ± 11.4	< 0.001
LDL-C(mg/dl) <sup>a</sup>	117.7 ± 34.4	110.6 ± 31.1	117.9 ± 33.2	121.9 ± 33.8	120.6 ± 38.1	< 0.001
UA (mg/dl) <sup>a</sup>	4.4 ± 1.2	4.3 ± 1.2	4.3 ± 1.2	4.5 ± 1.3	4.7 ± 1.8	< 0.001
SBP(mmHg) <sup>a</sup>	130.0 ± 21.2	125.8 ± 21.6	127.3 ± 19.7	131.5 ± 21.4	135.3 ± 20.9	< 0.001
DBP(mmHg) <sup>a</sup>	75.6 ± 12.0	72.1 ± 11.5	74.0 ± 11.5	76 .6 ± 11.9	79.7 ± 11.9	< 0.001
TyG index <sup>a</sup>	8.6 ± 0.6	8.20 ± 0.4	8.5 ± 0.5	8.7 ± 0.5	9.2 ± 0.6	< 0.001
BMI(kg/m <sup>2</sup> ) <sup>a</sup>	23.4 ± 3.8	19.4 ± 1.6	22.1 ± 1.3	24.2 ± 1.5	28.0 ± 3.5	< 0.001
TyG-BMI <sup>a</sup>	203.0 ± 39.9	158.5 ± 12.2	$186.2 \pm 6.6$	210.9 ± 7.9	256.2 ± 30.8	< 0.001
Hypertension,n(%)	2,701 (38.2%)	473 (26.8%)	547 (30.9%)	740 (41.9%)	941 (53.2%)	< 0.001
Dyslipidemia,n(%)	2,865 (40.5%)	326 (18.4%)	541 (30.6%)	801 (45.3%)	1,197 (67.7%)	< 0.001
Diabetes,n(%)	1,023 (14.5%)	99 (5.6%)	183 (10.4%)	258 (14.6%)	483 (27.3%)	< 0.001
CVDs,n(%)	1,774 (25.1%)	337 (19.1%)	410 (23.2%)	453 (25.6%)	574 (32.5%)	< 0.001
CHD,n(%)	1,355 (19.2%)	264 (14.9%)	311 (17.6%)	340 (19.2%)	440 (24.9%)	< 0.001
Stroke,n(%)	627 (8.9%)	101 (5.7%)	141 (8.0%)	180 (10.2%)	205 (11.6%)	< 0.001

<sup>a</sup> Data are mean ± SD; <sup>b</sup> Data are median (IQR); <sup>c</sup> One-way ANOVA test; Kruskal-Wallis rank sum test; Pearson's Chi-squared test; Q1, First Quartile; Q2, Second Quartile; Q3, Third Quartile; Q4, Fourth Quartile; TyG index, triglyceride-glucose index; BMI, body mass index; TyG-BMI, triglyceride glucose-body mass index; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; UA, uric acid; CVDs, cardiovascular diseases; CHD, coronary heart disease.



### FIGURE 2

Association between quartiles of the baseline TyG-BMI with the incidence of CVDs. Model 1: unadjusted model; Model 2: adjusted for age, sex; Model 3: adjusted for age, sex, education, marital status, smoking status, alcohol consumption, FBG, TG, TC, LDL-C, HDL-C, hypertension, diabetes, dyslipidemia. HR, Hazard Ratio; 95% CI, 95% Confidence Interval; TyG index, triglyceride–glucose index; BMI, body mass index; TyG-BMI index, triglyceride–glucose index x body mass index; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; CVDs, cardiovascular diseases; CHD, coronary heart disease.

CHD and stroke events, aHR, and 95% CI of Q4 vs Q1 in model 3 were 1.72(1.43-2.07), 1.52(1.12-2.06), respectively. Restricted cubic splines were used to explore the dose-response relationship between the TyG-BMI index and CVDs. The funnel plot presents the reference TyG-BMI index level as 198.36 with the non-linear P-value of 0.009. For subtypes, the reference value of the TyG-BMI index level were the same as for CVDs, with the nonlinear P < 0.001 for stroke (Supplementary Figure S1).

### Classes from the k-means clustering

After 4 years of follow-up until the third wave of the survey, kmeans clustering classified the TyG-BMI into three categories, as shown in Figure 3A. The total of TyG-BMI changed from 204.1 ± 38.9 in 2011 to 206.0 ± 38.6 in 2015 (n=4,151, P<0.001); and Figure 3B present the changes in each class: in class1 (n=1,510), the TyG-BMI changed from 168.2 ± 16.2 in 2011 to 168.8 ± 16.8 in 2015 (P=0.142), representing the participants with consistently low TyG-BMI levels; in class2 (n=1,794), the TyG-BMI changed from 208.0 ± 16.9 in 2011 to 211.8 ± 17.2 in 2015 (P<0.001), representing the participants with moderate TyG-BMI levels and a slowly increasing trend; in class3 (n=847), the TyG-BMI changed from 260.2 ± 29.6 in 2011 to 259.9 ± 26.8 in 2015 (P<0.001), representing the participants with the highest TyG-BMI levels and a slowly decreasing trend. The distribution of TyG-BMI in 2011 or 2015 is presented in Figures 3C, D.

# Baseline characteristics of participants according to change of TyG-BMI

Excluding samples without blood information, there were a total of 4,151 participants (average age of  $58.7 \pm 8.7$  years, 54.3% female) in 2015. After K-means clustering analysis, the comparison results by different categories are shown in Supplementary Table S1. Compared to the former crowd, this population exhibited higher levels of FBG

(100.7  $\pm$  30.4mg/dL), TG [112(81,163)mg/dL], BMI (23.7  $\pm$  3.6kg/m<sup>2</sup>), and TyG-BMI (206.0  $\pm$  38.6), along with a higher incidence of CVDs (1137,27.4%). The differences in covariates such as gender, marry status, and drinking status across the category groups were statistically significant (P<0.001). Based on the different categories, the incidence of CVD was 27.4% in total, with classes1 to 3 were 21.7%, 28.4%, 35.4%, respectively. For CHD and stroke, the incidences were 21.5% and 9.3%, respectively, with classes 1 to 3 showed incidences of CHD (16.9%, 22.1%, 28.3%) and stroke (6.8%, 9.9%, 12.6%). There were differences in the incidence of CVDs, coronary heart disease and stroke between groups based on TyG-BMI categories (P<0.001).

# Hazard ratios for incident CVDs according to change of TyG-BMI

Figure 4 shows the results of the Cox proportional hazards model. Compared to class 1, class3 had a higher risk of CVDs (HR 1.70; 95% CI 1.47–1.98). After multivariable adjustment in model 3, compared to class1, the adjusted hazard ratios (aHR) with 95% CI for class2 and class3 were 1.27(1.10-1.47), and 1.52(1.26-1.83). Both CHD and stroke show similar results across different categories, aHR, and 95% CI of class3 vs class1 were 1.58(1.27-1.96), 1.52(1.09-2.13), respectively. Restricted cubic splines were used to explore the dose-response relationship between the TyG-BMI and CVDs. The funnel plot presents the reference TyG-BMI index level as 199.26 and the non-linear P-value of 0.005. For subtypes, the reference value of the TyG-BMI index level were the same as for CVDs, with the nonlinear P-value of 0.007 for CHD (Supplementary Figure S2).

# ROC curve analysis of TyG-BMI, TyG, BMI prediction CVDs

ROC curve analysis indicates that TyG-BMI had the highest predictive ability for the incidence of CVDs among the three



x- and y-axes are principal components of the change in the TyG-BMI; **(B)** The change of TyG-BMI from 2012 to 2015: Cluster1, the TyG-BMI changed from  $168.16 \pm 16.21$  to  $168.77 \pm 16.82$ ; Cluster2, the TyG-BMI changed from  $207.95 \pm 16.92$  to  $211.84 \pm 17.20$ ; Cluster3, the TyG-BMI changed from  $206.19 \pm 29.60$  to  $259.90 \pm 26.78$ ; Total, the TyG-BMI changed from  $204.14 \pm 38.94$  to  $205.98 \pm 38.59$ ; **(C, D)** The distribution of TyG-BMI in 2011 or 2015: The normal distribution of TyG-BMI within each category was visible. PC, principal component, BMI, body mass index; TyG-BMI, triglyceride glucose-body mass index.

indicators, with an AUC of 0.647, slightly overmatching to TyG (AUC = 0.614) and BMI (AUC = 0.626) in the multivariate model (Figure 5).

In the multivariate model, the superior predictive performance of TyG-BMI compared to TyG and BMI was also observed in CVDs subtypes, with an AUC of 0.643 for predicting CHD and an AUC of 0.711 for predicting stroke.

### Subgroup analysis

The association of the variability of TyG-BMI and TyG-BMI with CVDs incidence stratified by different risk factors that was presented by Tables 2 and 3. After adjusting for confounding potential factors, smoking and marital status moderated the relationship between TyG-BMI change categories and cardiovascular events; and age, smoking and marital status moderated the association of TyG-BMI and cardiovascular events.

### Discussion

Among 7,072 middle-aged and elderly participants followed from 2011 to 2020, a significant relationship was observed between different quartiles of baseline TyG-BMI index and its variation over time with the incidence of CVDs in the cohort study. Furthermore, the association between the TyG-BMI index and CVDs remained significant even after adjusting for multiple CVDs risk factors. Additionally, the TyG-BMI index showed a similar positive correlation in assessing the risk of CVDs, CHD, and stroke. These findings highlight the predictive value of TyG-BMI levels and their patterns of change for predicting cardiovascular and cerebrovascular events in middle-aged and elderly individuals.

Based on our research findings, a higher TyG-BMI index compared to lower levels is associated with an increased overall risk of cardiovascular diseases in middle-aged and elderly individuals by approximately 20% to 60%. The impact of TyG-BMI index is even greater for CHD, with the risk attain 1.7 times, while the risk for

Subgroup	Model1	HR (95% CI)	Model2	HR (95% CI)	Model3	HR (95% CI)
CVDs						
Class1	÷	Reference	•	Reference	•	Reference
Class2		1.34 (1.17 - 1.53)		1.41 (1.23 - 1.61)		1.27 (1.10 - 1.47)
Class3		1.70 (1.47 - 1.98)		1.85 (1.59 - 2.16)	<b>—</b>	1.52 (1.26 - 1.83)
CHD						
Class1	•	Reference		Reference	•	Reference
Class2	<b></b>	1.33 (1.14 - 1.55)		1.37 (1.17 - 1.60)	F	1.25 (1.07 - 1.48)
Class3	H	1.73 (1.46 - 2.06)	<b>—</b>	1.82 (1.53 - 2.17)	F	1.58 (1.27 - 1.96)
Stroke						
Class1	•	Reference		Reference		Reference
Class2		1.44 (1.31 - 1.82)		1.62 (1.26 - 2.07)	• • • •	1.34 (1.02 - 1.75)
Class3		1.83 (1.41 - 2.39)	· · · · · · · · · · · · · · · · · · ·	2.23 (1.70 - 2.93)	·	1.52 (1.09 - 2.13)
0	5 1 1.5 2 2	5 0.5	1 1.5 2 2.5	1 F	5 1 1.5 2 2	2.5

Association between classes of the baseline TyG-BMI with the incidence of CVDs. Model 1: unadjusted model; Model 2: adjusted for age, sex; Model 3. adjusted for age sex education marital status smoking status alcohol consumption FBG TG TC LDL-C HDL-C hypertension diabetes dyslipidemia. HR, Hazard Ratio; 95% CI, 95% Confidence Interval; TyG index, triglyceride-glucose index; BMI, body mass index; TyG-BMI index, triglyceride-glucose index x body mass index; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; CVDs, cardiovascular diseases; CHD, coronary heart disease.

stroke also increased ranging from 30% to 50%. Our research findings indicate that the baseline TyG-BMI index can be used to identify individuals at risk for various cardiovascular diseases. If the TyG-BMI exceeds 198.36, individuals should be advised to take this as a warning and pay close attention to their cardiovascular health. Previous studies have indicated a positive correlation between TyG-BMI and CVDs (21, 24, 25), which is consistent with our findings. In a 10-year prospective cohort study involving 11,016 participants, it was found that TyG-BMI can reflect insulin resistance, and higher levels of TyG-BMI increased the risk of CVDs by 1.38 times (24). We confirmed this finding using a national cohort and analyzed different types of cardiovascular diseases in our study. Another recent study indicated that higher levels of TyG-BMI may be associated with an increased incidence of congestive heart failure, myocardial infarction, angina pectoris, and coronary artery disease (25). These studies are almost always consistent with our findings, and all demonstrate a significant correlation between TyG-BMI and CVDs events. Other related researches, restricted cubic spline curves indicated that a TyG-BMI index between 190 and 200 could serve as a reference for assessing disease risk (26, 27). These findings are generally consistent with our results.

We found that the TyG-BMI persistence group was at higher risk of CVDs, CHD, and stroke, compared to middle-aged and older adults in the group with lower levels of TyG-BMI index in our study. In previous studies, most focused on the relationship between the variation of the single TyG index and CVDs. A 10-year prospective cohort study indicated that the trajectory of TyG changes in the moderate-stable group was associated with the progression of carotid artery stenosis (CAS), while no association was observed in the high-increasing group (28). The results are inconsistent with ours. Results from the Kailuan study suggest that cumulative TyG is associated with an increased risk of CVDs (29). Another study indicated that variations in the TyG-WHtR are associated with the occurrence of CVDs, and that the progression of CVDS was significantly associated with moderate and high levels (30). These studies, as well as ours, provide evidence for the long-term monitoring of TyG-BMI variation and CVDs progression.

We performed subgroup analyses to validate whether our study applies to different populations. The results of the subgroup analyses were generally consistent with the main findings, except for smokers and unmarried individuals. A previous cohort study



(A), CHD (B) and Stroke (C)

### TABLE 2 Association of different categories of change in TyG-BMI with the risk of CVDs stratified by different factors.

C. have a	Change in the TyG-BMI, HR (95%CI)						
Subgroup	Class1 (1510)	Class2 (1794)	Class3 (847)	p for interaction			
Age				0.34			
<60	Reference	1.26 (1.01,1.57)	1.52 (1.15,2.00)				
≥60	Reference	1.26 (1.04,1.52)	1.40 (1.08,1.83)				
Gender				0.6			
Male	Reference	1.25 (1.01,1.56)	1.74 (1.28,2.37)				
Female	Reference	1.25 (1.03,1.52)	1.36 (1.07,1.72)				
Marital status				0.007			
Married	Reference	1.25 (1.07,1.46)	1.55 (1.27,1.89)				
Unmarried	Reference	1.32 (0.88,1.98)	0.82 (0.42,1.61)				
Education levels				0.901			
Primary school or below	Reference	1.23 (1.04,1.44)	1.41 (1.14,1.75)				
Middle school	Reference	1.35 (0.92,1.99)	1.52 (0.93,2.50)				
High school or above	Reference	1.24 (0.75,2.06)	1.82 (0.91,3.61)				
Smoking status				0.033			
Never smoker	Reference	1.21 (1.01,1.46)	1.48 (1.17,1.86)				
Former smoker	Reference	0.74 (0.44,1.22)	1.19 (0.64,2.20)				
Current smoker	Reference	1.59 (1.23,2.06)	1.50 (0.99,2.28)				
Drinking status				0.984			
Never drinking	Reference	1.23 (1.02,1.49)	1.40 (1.10,1.77)				
Former drinker	Reference	1.19 (0.73,1.92)	1.58 (0.84,2.97)				
Current drinker	Reference	1.33 (1.03,1.72)	1.64 (1.14,2.35)				
Hypertension				0.77			
Yes	Reference	1.33 (1.06,1.67)	1.52 (1.16,1.99)				
No	Reference	1.18 (0.98,1.43)	1.37 (1.04,1.82)				
Dyslipidemia				0.826			
Yes	Reference	1.35 (1.05,1.74)	1.60 (1.20,2.14)				
No	Reference	1.17 (0.98,1.41)	1.37 (1.04,1.81)				
Diabetes				0.979			
Yes	Reference	1.26 (0.81,1.98)	1.31 (0.81,2.12)				
No	Reference	1.26 (1.08,1.47)	1.52 (1.23,1.88)				

HR, Hazard Ratio; 95% CI, 95% Confidence Interval; TyG-BMI index, triglyceride–glucose index × body mass index; CVDs, cardiovascular diseases; All models adjusted for age, sex, education, marital status, smoking status, alcohol consumption, FBG, TG, TC, LDL-C, HDL-C, hypertension, diabetes, dyslipidemia.

showed that living alone was associated with a higher risk of developing CVDs (31). Additionally, a meta-analysis indicated that being unmarried was linked to an increased risk of CVDs (32). Moreover, multiple studies have shown that smoking increases the risk of developing CVDs (33–35). These findings suggest that smoking and being unmarried are associated with a higher risk of CVDs, indicating that TyG-BMI may not effectively predict high-risk CVD individuals within these populations.

IR is a systemic condition that affects multiple organs and insulin-regulatory pathways. It is characterized by a diminished insulin response despite elevated insulin levels (36). Previous studies have shown that IR is an important risk factor for CVDs (37, 38). IR impairs glycogen synthesis and protein catabolism in skeletal muscle and inhibits lipoprotein lipase activity in adipocytes, leading to increased release of free fatty acids(FFA) and inflammatory cytokines. The elevated FFA could accumulate as

<u>Cubarous</u>	TyG-BMI, HR (95%CI)						
Subgroup	Q1 (102.4-174.9)	Q2 (174.9,197.9)	Q3 (197.9,225.6)	Q4 (225.6,608.1)	p for interaction		
Age					0.043		
<60	Reference	1.22 (0.97,1.53)	1.49 (1.19,1.88)	1.64 (1.28,2.11)			
≥60	Reference	1.23 (1.03,1.48)	1.14 (0.94,1.39)	1.59 (1.27,1.98)			
Gender					0.965		
Male	Reference	1.25 (1.02,1.53)	1.33 (1.07,1.66)	1.68 (1.31,2.16)			
Female	Reference	1.18 (0.97,1.45)	1.27 (1.04,1.55)	1.57 (1.26,1.95)			
Marital status					0.042		
Married	Reference	1.29 (1.10,1.51)	1.34 (1.14,1.57)	1.70 (1.42,2.02)			
Unmarried	Reference	0.90 (0.63,1.30)	1.08 (0.73,1.59)	1.10 (0.65,1.88)			
Education levels					0.852		
Primary school or below	Reference	1.17 (0.99,1.37)	1.23 (1.04,1.46)	1.52 (1.26,1.84)			
Middle school	Reference	1.25 (0.87,1.80)	1.28 (0.88,1.87)	1.78 (1.19,2.66)			
High school or above	Reference	1.77 (1.04,3.01)	1.91 (1.12,3.27)	2.17 (1.17,4.00)			
Smoking status					0.025		
Never smoker	Reference	1.24 (1.02,1.50)	1.36 (1.12,1.65)	1.73 (1.40,2.14)			
Former smoker	Reference	0.87 (0.57,1.34)	0.72 (0.46,1.11)	1.22 (0.76,1.97)			
Current smoker	Reference	1.36 (1.07,1.74)	1.49 (1.14,1.94)	1.53 (1.10,2.14)			
Drinking status					0.091		
Never drinking	Reference	1.23 (1.01,1.49)	1.35 (1.11,1.65)	1.68 (1.36,2.07)			
Former drinker	Reference	0.77 (0.50,1.19)	0.65 (0.40,1.07)	0.92 (0.55,1.55)			
Current drinker	Reference	1.38 (1.08,1.76)	1.45 (1.12,1.88)	1.72 (1.26,2.33)			
Hypertension					0.617		
Yes	Reference	1.33 (1.06,1.68)	1.31 (1.04,1.65)	1.64 (1.28,2.09)			
No	Reference	1.14 (0.96,1.37)	1.29 (1.06,1.57)	1.53 (1.21,1.94)			
Dyslipidemia					0.71		
Yes	Reference	1.37 (1.03,1.81)	1.41 (1.07,1.85)	1.73 (1.31,2.29)			
No	Reference	1.13 (0.96,1.34)	1.19 (0.99,1.44)	1.51 (1.21,1.89)			
Diabetes					0.085		
Yes	Reference	2.20 (1.29,3.73)	1.65 (0.97,2.81)	2.17 (1.28,3.67)			
No	Reference	1.17 (1.01,1.36)	1.31 (1.12,1.54)	1.61 (1.34,1.93)			

HR, Hazard Ratio; 95% CI, 95% Confidence Interval; TyG-BMI index, triglyceride–glucose index × body mass index; CVDs, cardiovascular diseases; All models adjusted for age, sex, education, marital status, smoking status, alcohol consumption, FBG, TG, TC, LDL-C, HDL-C, hypertension, diabetes, dyslipidemia.

lipids, causing their influx into the liver and other organs, further exacerbating IR and contributing to systemic IR (39, 40). At the same time, overweight and obesity, as key factors in metabolic disorders, not only increase the risk of CVDs but also lead to IR by mediating the flow of FFA due to the accumulation of body fat (41, 42). HEC is considered the gold standard for assessing insulin resistance; however, its complex and costly procedure limits its widespread clinical use (14–16). There is an urgent need for a

simpler alternative method. Recently, TyG-BMI index has emerged as a novel alternative indicator for IR. Due to its inclusion of FBG, TG, and BMI, it offers greater applicability (43–46).

There are several advantages to this study. Firstly, we utilized data from a nationwide prospective cohort study of middle-aged and elderly individuals. Secondly, compared to the gold standard for IR, TyG-BMI provides an economical, simple, and effective alternative method. Additionally, we not only conducted analyses in

10.3389/fendo.2025.1514660

middle-aged and elderly populations, but also performed subgroup analyses across different demographic groups. Finally, we used repeated measures data to explore the relationship between changes in TyG-BMI and the incidence of CVDs and its subtypes. We also adjusted for multiple potential confounding factors to minimize their impact on the results.

However, our research also has some limitations. Firstly, our study is observational and lacks intervention and randomization, and could not completely exclude all unmeasurable confounders. Due to the nature of observational studies, we may not be able to establish causal relationships, which need to be verified in future research. Secondly, our study population was limited to individuals over 45 years old, and cannot be better generalized to other age groups. Additionally, CVDs were primarily defined as self-reported CHD and stroke in the CHARLS data, which may be making it difficult to verify their accuracy. However, previous studies have shown that self-reports are generally consistent with medical diagnosis records, indicating that the risk of misreporting bias is minimal (47).

### Conclusion

In the prospective study of middle-aged and elderly populations, we demonstrated that high levels of TyG-BMI is an independent risk factor for CVDs, CHD, and stroke, whether due to elevated baseline TyG-BMI levels or fluctuations that remain at high levels. Additionally, TyG-BMI could serve as a simple, accessible, cost-effective, and relatively reliable alternative indicator for IR. Therefore, detecting long-term changes in TyG-BMI could aid in the early identification of high-risk individuals, thereby preventing the occurrence of various CVDs.

### Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: http://charls.pku.edu.cn.

### Ethics statement

The studies involving humans were approved by Peking University Ethics Committee. The IRB approval numbers were IRB00001052-11015 and IRB00001052-11014. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

# Author contributions

JQ: Writing – original draft, Writing – review & editing. XC: Writing – original draft, Writing – review & editing. JP: Writing – original draft, Writing – review & editing. HF: Writing – original draft, Writing – review & editing. ZL: Writing – original draft, Writing – review & editing. FC: Writing – original draft, Writing – review & editing. QC: Writing – original draft, Writing – review & editing. YZ: Writing – original draft, Writing – review & editing. WC: Writing – original draft, Writing – review & editing. FS: Writing – original draft, Writing – review & editing. HJ: Writing – original draft, Writing – review & editing. Supervision.

# Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Noncommunicable Chronic Diseases-National Science and Technology Major Project. (grant no.2023ZD0503500).

# Acknowledgments

We sincerely thank all the members involved in the CHARLS project for their efforts and the data they provided.

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# **Generative AI statement**

The author(s) declare that no Generative AI was used in the creation of this manuscript.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2025. 1514660/full#supplementary-material

### SUPPLEMENTARY FIGURE 1

Restricted cubic spline plots for associations of baseline TyG-BMI index levels with CVDs and subtypes among 7,072 participants. HRs and 95%Cls for A (CVDs), B(CHD), and C(Stroke) based on restricted cubic splines for baseline TyG index; HRs and 95%Cls were calculated using Cox proportional-hazards models after adjustment for age. HRs, Hazard Ratios; 95%Cls, 95% Confidence Intervals; CVDs, cardiovascular diseases; CHD, coronary heart disease.

#### SUPPLEMENTARY FIGURE 2

Restricted cubic spline plots for associations of baseline TyG-BMI index levels with CVDs and subtypes among 4,151 participants. HRs and 95%Cls for A (CVDs), B(CHD), and C(Stroke) based on restricted cubic splines for baseline

TyG index; HRs and 95%Cls were calculated using Cox proportional-hazards models after adjustment for age. HRs, Hazard Ratios; 95%Cls, 95% Confidence Intervals; CVDs, cardiovascular diseases; CHD, coronary heart disease.

# References

1. Kaminsky LA, German C, Imboden M, Ozemek C, Peterman JE, Brubaker PH. The importance of healthy lifestyle behaviors in the prevention of cardiovascular disease. *Prog Cardiovasc Dis.* (2022) 70:8–15. doi: 10.1016/j.pcad.2021.12.001

2. Mangione CM, Barry MJ, Nicholson WK, Cabana M, Chelmow D, Coker TR, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. *Jama*. (2022) 328:746–53. doi: 10.1001/jama.2022.13044

3. Kivimaki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. *Nat Rev Cardiol.* (2018) 15:215-29. doi: 10.1038/nrcardio.2017.189

4. Sacco RL, Roth GA, Reddy KS, Arnett DK, Bonita R, Gaziano TA, et al. The heart of 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: A modeling study from the american heart association and world heart federation. *Circulation*. (2016) 133:e674–90. doi: 10.1161/CIR.00000000000395

5. Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. *Nat Rev Cardiol.* (2019) 16:203–12. doi: 10.1038/s41569-018-0119-4

6. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. *J Am Coll Cardiol.* (2020) 76:2982–3021. doi: 10.1016/j.jacc.2020.11.010

7. Rosenblit PD. Extreme atherosclerotic cardiovascular disease (ASCVD) risk recognition. *Curr Diabetes Rep.* (2019) 19:61. doi: 10.1007/s11892-019-1178-6

8. England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. *Bmj.* (2018) 361:k1036. doi: 10.1136/bmj.k1036

9. Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. *Nat Rev Rheumatol.* (2020) 16:361-79. doi: 10.1038/s41584-020-0428-y

10. Choi S. The potential role of biomarkers associated with ASCVD risk: riskenhancing biomarkers. J Lipid Atheroscler. (2019) 8:173-82. doi: 10.12997/ jla.2019.8.2.173

11. D'Agostino RS, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. (2008) 117:743–53. doi: 10.1161/CIRCULATIONAHA.107.699579

12. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*. (2009) 58:773–95. doi: 10.2337/db09-9028

13. Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. *Metabolism*. (2021) 119:154766. doi: 10.1016/j.metabol.2021.154766

14. Wang T, Li M, Zeng T, Hu R, Xu Y, Xu M, et al. Association between insulin resistance and cardiovascular disease risk varies according to glucose tolerance status: A nationwide prospective cohort study. *Diabetes Care.* (2022) 45:1863–72. doi: 10.2337/ dc22-0202

15. Chang Y, Kim CK, Kim MK, Seo WK, Oh K. Insulin resistance is associated with poor functional outcome after acute ischemic stroke in non-diabetic patients. *Sci Rep.* (2021) 11:1229. doi: 10.1038/s41598-020-80315-z

16. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabetes Med. (2002) 19:527–34. doi: 10.1046/j.1464-5491.2002.00745.x

17. Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. *Cardiovasc Diabetol.* (2022) 21:68. doi: 10.1186/s12933-022-01511-x

18. Alizargar J, Bai CH, Hsieh NC, Wu SV. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. *Cardiovasc Diabetol.* (2020) 19:8. doi: 10.1186/s12933-019-0982-2

19. Zhou Z, Liu Q, Zheng M, Zuo Z, Zhang G, Shi R, et al. Comparative study on the predictive value of TG/HDL-C, TyG and TyG-BMI indices for 5-year mortality in critically ill patients with chronic heart failure: a retrospective study. *Cardiovasc Diabetol.* (2024) 23:213. doi: 10.1186/s12933-024-02308-w

20. Chen T, Wan H, Luo Y, Chen L. Association of triglyceride-glucosebody mass index with all-cause and cardiovascular mortality among individuals with chronic kidney disease. Sci Rep. (2024) 14:20593. doi: 10.1038/s41598-024-71579-w

21. Miao H, Zhou Z, Yang S, Zhang Y. The association of triglyceride-glucose index and related parameters with hypertension and cardiovascular risk: a cross-sectional study. *Hypertens Res.* (2024) 47:877–86. doi: 10.1038/s41440-023-01502-9

22. Sinaga KP, Yang M. Unsupervised K-means clustering algorithm. *IEEE Access*. (2020) 8:80716–27. doi: 10.1109/ACCESS.2020.2988796

23. Zhao W, Deng C, Ngo C. k -means: A revisit. *Neurocomputing*. (2018) 291:195–206. doi: 10.1016/j.neucom.2018.02.072

24. Wang R, Cheng X, Tao W. Association between triglyceride glucose body mass index and cardiovascular disease in adults: evidence from NHANES 2011- 2020. Front Endocrinol (Lausanne). (2024) 15:1362667. doi: 10.3389/fendo.2024.1362667

25. Dang K, Wang X, Hu J, Zhang Y, Cheng L, Qi X, et al. The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003-2018. *Cardiovasc Diabetol.* (2024) 23:8. doi: 10.1186/s12933-023-02115-9

26. Dou J, Guo C, Wang Y, Peng Z, Wu R, Li Q, et al. Association between triglyceride glucose-body mass and one-year all-cause mortality of patients with heart failure: a retrospective study utilizing the MIMIC-IV database. *Cardiovasc Diabetol.* (2023) 22:309. doi: 10.1186/s12933-023-02047-4

27. Fan C, Guo M, Chang S, Wang Z, An T. Elevated TyG-BMI index predicts incidence of chronic kidney disease. *Clin Exp Med.* (2024) 24:203. doi: 10.1007/s10238-024-01472-3

28. Yu H, Tao L, Li YG, Yang L, Liu D, Wang Y, et al. Association between triglyceride-glucose index trajectories and carotid atherosclerosis progression. *Cardiovasc Diabetol.* (2023) 22:130. doi: 10.1186/s12933-023-01847-y

29. Cui H, Liu Q, Wu Y, Cao L. Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study. *Cardiovasc Diabetol.* (2022) 21:22. doi: 10.1186/s12933-022-01456-1

30. Ren Q, Huang Y, Liu Q, Chu T, Li G, Wu Z. Association between triglyceride glucose-waist height ratio index and cardiovascular disease in middle-aged and older Chinese individuals: a nationwide cohort study. *Cardiovasc Diabetol.* (2024) 23:247. doi: 10.1186/s12933-024-02336-6

31. Chen R, Zhan Y, Pedersen N, Fall K, Valdimarsdóttir UA, Hägg S, et al. Marital status, telomere length and cardiovascular disease risk in a Swedish prospective cohort. *Heart.* (2020) 106:267–72. doi: 10.1136/heartjnl-2019-315629

32. Wong CW, Kwok CS, Narain A, Gulati M, Mihalidou AS, Wu P, et al. Marital status and risk of cardiovascular diseases: a systematic review and meta-analysis. *Heart.* (2018) 104:1937–48. doi: 10.1136/heartjnl-2018-313005

33. Wilcox NS, Amit U, Reibel JB, Berlin E, Howell K, Ky B. Cardiovascular disease and cancer: shared risk factors and mechanisms. *Nat Rev Cardiol*. (2024) 21:617–31. doi: 10.1038/s41569-024-01017-x

34. Hobbs FD. Prevention of cardiovascular diseases. BMC Med. (2015) 13:261. doi: 10.1186/s12916-015-0507-0

35. Kalkhoran S, Benowitz NL, Rigotti NA. Reprint of: prevention and treatment of tobacco use: JACC health promotion series. J Am Coll Cardiol. (2018) 72:2964–79. doi: 10.1016/j.jacc.2018.10.020

36. Artunc F, Schleicher E, Weigert C, Fritsche A, Stefan N, Haring HU. The impact of insulin resistance on the kidney and vasculature. *Nat Rev Nephrol.* (2016) 12:721–37. doi: 10.1038/nrneph.2016.145

37. Moshkovits Y, Rott D, Chetrit A, Dankner R. The association between insulin sensitivity indices, ECG findings and mortality: a 40-year cohort study. *Cardiovasc Diabetol.* (2021) 20:97. doi: 10.1186/s12933-021-01284-9

38. Girousse A, Tavernier G, Valle C, Moro C, Mejhert N, Dinel AL, et al. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. *PloS Biol.* (2013) 11:e1001485. doi: 10.1371/journal.pbio.1001485

39. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. *Cardiovasc Diabetol.* (2018) 17:122. doi: 10.1186/s12933-018-0762-4

40. Laakso M, Kuusisto J. Insulin resistance and hyperglycemia in cardiovascular disease development. Nat Rev Endocrinol. (2014) 10:293–302. doi: 10.1038/nrendo.2014.29

41. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care.* (2009) 32 Suppl 2:S157-63. doi: 10.2337/dc09-S302

42. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. (2011) 121:2111–17. doi: 10.1172/JCI57132

43. Lee J, Kim B, Kim W, Ahn C, Choi HY, Kim JG, et al. Lipid indices as simple and clinically useful surrogate markers for insulin resistance in the U.S. population. *Sci Rep.* (2021) 11:2366. doi: 10.1038/s41598-021-82053-2

44. Ramírez-Vélez R, Pérez-Sousa M, González-Ruíz K, Cano-Gutierrez C, Schmidt-RioValle J, Correa-Rodríguez M, et al. Obesity- and lipid-related parameters in the identification of older adults with a high risk of prediabetes according to the american diabetes association: an analysis of the 2015 health, well-being, and aging study. *Nutrients.* (2019) 11:2654. doi: 10.3390/nu11112654

45. Tuo X, Yuan J, Wang XH, Xin Z. Identifying the insulin resistance index in nondiabetic Chinese subjects. *Med (Baltimore)*. (2020) 99:e19023. doi: 10.1097/MD.000000000019023

46. Lim J, Kim J, Koo SH, Kwon GC. Comparison of triglyceride glucose index, and related parameters to predict insulin resistance in Korean adults: An analysis of the 2007-2010 Korean National Health and Nutrition Examination Survey. *PloS One.* (2019) 14:e0212963. doi: 10.1371/journal.pone.0212963

47. Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: the English longitudinal study of ageing. Int J Epidemiol. (2013) 42:1640–48. doi: 10.1093/ije/dys168